New study examines U.S. hospitals’ experiences in public health reporting

Full 1-year results have now been published for the pivotal SELECT-AXIS 2 trial that underpinned the FDA approval of upadacitinib (Rinvoq) for non-radiographic axial spondyloarthritis

No­vavax is cut­ting 12% of its full-time em­ploy­ees and con­trac­tors, and its to­tal work­force will now be ap­prox­i­mate­ly 30% small­er than what it was a

The FDA will con­vene its on­col­o­gy ad­vi­so­ry com­mit­tee in Oc­to­ber to dis­cuss Lumakras, Am­gen’s KRAS-in­hibit­ing oral med­ica­tion as a sec­ond-line treat­ment for KRAS G12C-mu­tat­ed non-small